SAKAR
Sakar Healthcare share price & financials
- Price
- ₹803.6
- Market cap
- ₹2.1k Cr
- Sector
- Healthcare
- Calls analysed
- 4
Sakar Healthcare Limited Q1 FY27
What went well
- Revenue from operations for Q1 FY27 stood at INR7,297 lakhs, delivering a year-on-year growth of 38%.
- EBITDA increased by 67% to INR2,125 lakhs, while EBITDA margins improved to 29%.
- Profit after tax stood at INR1,028 lakhs, recording a growth of 120% over the corresponding quarter.
What to watch
- Initial 'teething problems' related to logistics and serialization processes for first-time MA dispatches.
What Sakar Healthcare Limited does
Sakar Healthcare is a Gujarat-based, API-integrated pharmaceutical manufacturer that has evolved from a contract manufacturer into a vertically integrated oncology player. It earns through three lines: CDMO/CMO manufacturing services for large multinational and domestic pharma companies, exports of its own branded and generic formulations across regulated and emerging markets, and licensing/technology-transfer of its developed product dossiers to partners. Its EU-GMP and WHO-GMP certified facilities in Gujarat produce oral solids, oral liquids, sterile (liquid and lyophilised) injections and APIs, with a dedicated integrated API-to-finished-dosage oncology unit at Bavla.
Segments
- CDMO / CMO Services
- Own Brand Exports
- Licensing / Product Development
- Manufacturing plants
- 4
- Country presence (own-brand exports)
- 60+ countries
- International partner network
- 75+ partners
- Oncology molecules developed
- 55 (32 dossiers ready for global launch)
- Product registrations (Marketing Authorisations)
- 292+
- Dossiers filed (in process)
- 300+
Guidance record · Q1 FY27
what the last two calls moved 23 tracked 2 delivered 2 missed 19 open- EBITDA Margin delivered said Q2 FY26 Promised: 25% for FY26 Q1 FY27: This is a closed promise from a prior fiscal year. The final verdict remains 'achieved'.
- Revenue missed said Q2 FY26 Promised: ₹280 crores for FY26 Q1 FY27: This is a closed promise from a prior fiscal year. The final verdict remains 'missed'.
- Oncology EBITDA Margin revised up said Q3 FY26 Promised: 30% EBITDA margin Q1 FY27: Management guided that margins will be 'soon crossing the 30% margin EBITDA' by the end of FY27, strengthening the previously diluted guidance.
All 23 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 37.7%, net profit up 100.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 43 | 43 | 50 | 53 | 58 +35% | 70 +63% | 71 +42% | 73 +38% |
| EBITDA | 12 | 12 | 16 | 13 | 11 −8% | 19 +58% | 26 +63% | 21 +62% |
| Net profit | 5 | 5 | 6 | 5 | 5 +0% | 10 +100% | 11 +83% | 10 +100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +239.8% 1Y
1Y: ₹341 on 10 Sept 2025 → ₹1,158.55. High ₹1,158.55 (11 Sept 2026), low ₹334.3 (12 Sept 2025).
How the price took the results
close before → close after
- Q1 FY27
- +0.4%
- 29 Jul
- Q4 FY26
- −3.2%
- 22 May
- Q3 FY26
- +1.3%
- 11 Feb
- Q2 FY26
- +2.2%
- 11 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 23.7% a year over 3 years, FY23 to FY26. Operating margin widened to 27.4%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹133 Cr | ₹153 Cr | ₹177 Cr | ₹252 Cr |
| Operating profit | ₹34 Cr | ₹38 Cr | ₹51 Cr | ₹69 Cr |
| Operating margin | 25.2% | 24.8% | 28.8% | 27.4% |
| Interest | ₹6 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| Depreciation | ₹15 Cr | ₹18 Cr | ₹20 Cr | ₹24 Cr |
| Net profit | ₹13 Cr | ₹12 Cr | ₹18 Cr | ₹31 Cr |
| Net margin | 9.6% | 7.8% | 10.2% | 12.3% |
| Cash from operations | ₹33 Cr | ₹24 Cr | ₹34 Cr | ₹49 Cr |
| Free cash flow | ₹-49 Cr | ₹-35 Cr | ₹2 Cr | ₹21 Cr |
| ROCE | 9.0% | 7.0% | 9.0% | 13.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹16 Cr | ₹17 Cr | ₹19 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr |
| Reserves | ₹83 Cr | ₹110 Cr | ₹154 Cr | ₹241 Cr | ₹281 Cr | ₹302 Cr |
| Borrowings | ₹43 Cr | ₹93 Cr | ₹119 Cr | ₹79 Cr | ₹72 Cr | ₹55 Cr |
| Other liabilities | ₹37 Cr | ₹47 Cr | ₹44 Cr | ₹47 Cr | ₹73 Cr | ₹101 Cr |
| Total liabilities | ₹178 Cr | ₹268 Cr | ₹336 Cr | ₹389 Cr | ₹449 Cr | ₹481 Cr |
| Fixed assets | ₹69 Cr | ₹205 Cr | ₹267 Cr | ₹314 Cr | ₹325 Cr | ₹326 Cr |
| Capital work in progress | ₹49 Cr | ₹1 Cr | ₹6 Cr | ₹0 Cr | ₹17 Cr | ₹4 Cr |
| Investments | ₹0 Cr | ₹7 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹60 Cr | ₹55 Cr | ₹60 Cr | ₹74 Cr | ₹107 Cr | ₹151 Cr |
| Total assets | ₹178 Cr | ₹268 Cr | ₹336 Cr | ₹389 Cr | ₹449 Cr | ₹481 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
What the price assumes
AttractiveTo justify its price of ₹1159, this stock must grow earnings at 39% every year for 7 years. Our analysis caps realistic growth at ~46%. At that growth it is worth ₹1589 — upside of 37%.
- Growth the price implies
- 38.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 45.7% a year
- net profit, FY23–FY26
- The gap
- -0.1 pp
- 37% downside if it only repeats history
All earnings calls (4)
Read the Q1 FY27 call →Learn to analyse Sakar Healthcare Limited
Guides on how to read this kind of business and the numbers that matter.